The regulatory firehose, monitored.

Every Health Canada approval, PMPRB update, pCPA move, and HTA recommendation as it lands. Machine-assisted and labelled as such — the read on what it means lives in Analysis.

Machine-assisted digest

Today · Jun 13

12:40 p.m.

pCPA

pCPA initiates negotiations for a GLP-1 receptor agonist in type 2 diabetes

The Alliance has opened a negotiation file; participating jurisdictions will proceed to listing decisions on conclusion.

Read the analysis →

10:40 a.m.

Health Canada · NOC

Notice of Compliance issued for a biosimilar to a reference monoclonal antibody

Market authorization granted; product becomes eligible for provincial formulary review.

Read the analysis →

8:40 a.m.

CADTH

Conditional reimbursement recommendation for an oncology agent, pending price reduction

Recommendation to reimburse is conditional on a lower negotiated price and defined clinical criteria.

Read the analysis →

5:40 a.m.

Ontario (OHIP+)

Ontario adds a chronic-condition therapy to the formulary under limited-use criteria

Listing carries limited-use codes restricting reimbursement to a defined patient subgroup.

Yesterday · Jun 12

12:40 p.m.

PMPRB

Updated guidance published on the price review framework; 30-day consultation opens

Draft guidance revises the analytical approach to price review; stakeholder comments accepted through mid-July.

Read the analysis →

10:40 a.m.

RAMQ (Québec)

Specialty rare-disease therapy added under the exceptional patient measure

Access granted via individual patient authorization ahead of a general listing decision.

Jun 10

INESSS

INESSS recommends against listing for a chronic-condition therapy, citing cost-effectiveness uncertainty

Recommendation cites insufficient evidence of value at the submitted price.

The Wire tells you what happened.

The Analysis — and the Connector — tell you what it means for distribution, reimbursement, and channel strategy.

Get the Connector